Evidence map›Paper›PMID 35544469›Full record

ArticlemAbs

The human antibody sequence space and structural design of the V, J regions, and CDRH3 with Rosetta.

Samuel Schmitz, Emily A Schmitz, James E Crowe, Jens Meiler

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Samuel SchmitzDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, United States.ORCID 0000-0001-5314-6095
Emily A SchmitzCenter of Structural Biology, Vanderbilt University, Nashville, Tennessee, United States.ORCID 0000-0002-5122-8991
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States.ORCID 0000-0002-0049-1079
Jens MeilerDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, United States.ORCID 0000-0001-8945-193X
Vanderbilt University · USVanderbilt University Medical Center · US

Funding

Structure based design of trimer interface epitope focused universal influenza vaccinesU01AI150739 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2020 to 2024
$6.1M
Epitope-Based Design and Modified RNA Platform for Bivalent Marburgvirus VaccineR01AI141661 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER, CROWE, JAMES E · 2019 to 2023
$3.9M
NIAID NIH HHS R01 AI141661NIAID NIH HHS U01 AI150739
6 · The paper itself

Abstract

The human adaptive immune response enables the targeting of epitopes on pathogens with high specificity. Infection with a pathogen induces somatic hyper-mutation and B-cell selection processes that govern the shape and diversity of the antibody sequence landscape. To date, even the largest immunome repertoires of adaptive immune receptors acquired by next-generation sequencing cannot fully capture the vast antibody sequence space of a single individual, which is estimated to be at least 10

Indexed as

Amino AcidsAntibodiesAmino Acid SequenceAnimalsBayes TheoremComplementarity Determining RegionsHumansMiceNucleotidesAmino AcidsAntibodiesComplementarity Determining RegionsNucleotidesHuman-likeness; antibody design; rosetta; immunome repertoire; biostatistics; HumanizationABBREVIATIONS

Identifiers

PMID35544469
PMCPMC9103704
OpenAlexW4280565570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.